DRG Market Assessment reports

Migraine, which afflicts approximately 34 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…

Since 2015, the genericized Parkinson’s disease (PD) market has witnessed the launch of nearly a dozen unique brands (e.g., Inbrija, Kynmobi, Nourianz), and several more are on the horizon,…

Clarivate publishes content on Angelman syndrome and its current and future management, patient journey, and the competitive landscape in the U.S., EU5, and China markets between 2021 and 2031

DSWPD is a type of circadian rhythm sleep-wake disorder in which the sleep-wake cycle is delayed. DSWPD occurs more commonly in adolescents than in adults. In addition, the condition is…

Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly…

The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…

Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to Clarivate epidemiology, is a heterogeneous condition requiring individualized…

The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilars developers must ensure that they are equipped with the necessary…

Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 600 currently available and novel biosimilar products, detailing…

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain…

Executive Insights report on current medical practice, unmet need, and emerging treatments for spinocerebellar ataxia in the United States, Europe, and China.